MeiraGTx Holdings (MGTX) Shares Outstanding (2017 - 2026)
MeiraGTx Holdings' (MGTX) quarterly Shares Outstanding (Entity) came in at $81.1 million in Q4 2025, up 3.47% YoY from $78.4 million in Q4 2024, and up 0.8% on a QoQ basis from $80.5 million in Q3 2025.
Analysis
MeiraGTx Holdings (MGTX) Shares Outstanding (2017 - 2026) Analysis & Trends
MeiraGTx Holdings (MGTX) has 9 years of Shares Outstanding (Entity) data on file, last reported at $81.1 million in Q4 2025.
- Quarterly Shares Outstanding (Entity) rose 3.47% year-over-year to $81.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $81.1 million (up 3.47% YoY) and the FY2025 annual result came in at $81.1 million, up 3.47% from the prior year.
- Shares Outstanding (Entity) climbed to $81.1 million in Q4 2025, from $80.5 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $81.1 million in Q4 2025 to a low of $44.3 million in Q1 2021.
- A 5-year average of $59.9 million and a median of $59.6 million in 2023 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2021 — Shares Outstanding (Entity) increased 0.81% — and 2023, when it soared 33.25%.
- Tracing MGTX's Shares Outstanding (Entity) over 5 years: stood at $44.5 million in 2021, then grew by 8.82% to $48.5 million in 2022, then soared by 31.2% to $63.6 million in 2023, then gained by 23.26% to $78.4 million in 2024, then gained by 3.47% to $81.1 million in 2025.
- The last three Shares Outstanding (Entity) figures came in at $81.1 million (Q4 2025), $80.5 million (Q3 2025), and $80.4 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 61.30 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 398.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 210.89 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 111.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 445.06 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 217.35 Mn |
| 10 | MeiraGTx Holdings | 1.27 Bn | 1.13 Bn | 315.67 Mn | 91.42 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 91.42 Mn |
| Dec 31, 2025 | 80.43 Mn |
| Sep 30, 2025 | 80.95 Mn |
| Jun 30, 2025 | 80.59 Mn |
| Mar 31, 2025 | 79.03 Mn |
| Dec 31, 2024 | 69.82 Mn |
| Sep 30, 2024 | 71.63 Mn |
| Jun 30, 2024 | 64.38 Mn |
| Mar 31, 2024 | 64.07 Mn |
| Dec 31, 2023 | 56.49 Mn |
| Sep 30, 2023 | 59.53 Mn |
| Jun 30, 2023 | 55.35 Mn |
| Mar 31, 2023 | 48.64 Mn |
| Dec 31, 2022 | 45.18 Mn |
| Sep 30, 2022 | 44.69 Mn |
| Jun 30, 2022 | 44.67 Mn |
| Mar 31, 2022 | 44.50 Mn |
| Dec 31, 2021 | 44.14 Mn |
| Sep 30, 2021 | 44.17 Mn |
| Jun 30, 2021 | 44.14 Mn |